Illumina (NASDAQ:ILMN) Issues Earnings Results, Misses Expectations By $0.06 EPS

Illumina (NASDAQ:ILMN) posted its earnings results on Thursday. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06), Zacks reports. Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%.

Illumina Stock Performance

NASDAQ ILMN opened at $111.06 on Friday. The business’s 50-day simple moving average is $136.70 and its 200-day simple moving average is $135.29. The firm has a market capitalization of $17.61 billion, a P/E ratio of -14.46 and a beta of 1.10. Illumina has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent research reports. Royal Bank of Canada dropped their price objective on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price target for the company in a report on Thursday, October 17th. Guggenheim dropped their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday. JPMorgan Chase & Co. boosted their target price on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target on the stock in a research note on Thursday, October 17th. Nine equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $161.40.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.